thought alvogen revlimid settlement
agreement remov addit overhang regard potenti gener entri back iss recommend
favor bmy/celg deal see bmy/celg iss support celgen deal remov starboard proxi
solicit view announc celgen settlement ith alvogen revlimid patent anoth posit remov
anoth overhang stock reduc risk competit moreov hile settlement allow volume-limit
sale period impact revenu grow th like much less signific natco agreement given
much low er volum limit peak volum singl digit percentag vs natco overal feel ith expect
signific revlimid eros alreadi assum increment volum loss settlement period good trade-off low ere
risk near-term competit follow ing remov addit uncertainti continu see long-term strateg
financi rational favor bristol acquisit celgen ith increas support remain confid sharehold ill like vote
favor april maintain ew rate pt maintain ow rate celg pt
view increment revlimid eros result today settlementw hich believ like follow ed other
includ dr reddi see celg/bmi ptab declin dr reddi ipr review revlimid md patent ill sever affect
bristol de-lever strategi post-deal given bristol manag guidanc reiter today ceo/cfo call seri discuss
 ith ceo giovanni caforio aggress debt paydow lead debt/ebitda ratio
major effort ill complet alvogen/natco settlement go effect begin impact revlimid sale base
pro forma analysi see combin compani achiev leverag target ith revlimid sale eros
singl digit rang assumpt increment celgen cash flow direct tow ard deal debt assum
aggress addit sale loss year could expect debt/ebitda ratio increas fact
even ith significantli higher eros assumpt combin compani success reduc leverag target rang
given strong cash flow expect earli year deal prior gener revlimid competit ith dr reddi legal
battl continu play potenti settlement case even ith term similar natco settlement ould similarli
remov nearer-term risk revlimid unlik affect feasibl pend bristol deal
let us know question concern geoff greg jason olivia scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu use blend averag price/grow th basi base averag larg cap
global therapeut group hich view appropri given primari focu specialti drug/biotechnology-ori
compani discount cash flow analysi assign equal eight tw methodolog deriv price target
per share
risk may imped achiev barclay research valuat price grow th prospect
increasingli depend deliveri immuno-oncolog pipelin setback delay could pose risk stock field
immuno-oncolog get increasingli competit bristol leadership challeng major player particularli
merck keytruda competit disadvantag term clinic develop regulatori timelin could put pressur
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog price target base price-to-earnings multipl support sum-of-th part npv analysi
use base busi assign revlimid pom/ thal/ vidaza otezla
abraxan pipelin assign luspatercept ozanimod combin ith
equity/ platform valu net cash support pt
risk may imped achiev barclay research valuat price commerci risk increas
preval mm revlimid strong competit posit provid signific tailw ind could drive upsid forecast
mani product biotech industri high price point celgen product includ revlimid differ
surpris certain region select payor segment pushback cost
decis made use less expens treatment altern increas adopt strategi could neg impact
celgen oper perform share price clinic risk celgen deep pipelin drug candid intern
partner compani develop across rang diseas mani drug early-to-mid stage
develop could fail meet target endpoint trial fail demonstr meaning clinic benefit
outcom could put impair celgen abil launch new drug could pressur share perform litig patent
risk patent relat celgen key product revlimid focu on-going litig hich could lead market entri
gener revlimid prior compani expect gener revlimid enter market prior street expect revlimid
sale could fall celgen share ould neg impact gener celgen reli patent protect
invest drug develop gener entrant celgen brand product could harm futur sale regulatori risk
celgen broad pipelin could result posit late stage data ever posit data guarante fda
ema ill grant approv delay timelin inabl gain approv could significantli impact celgen futur sale
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
